Justin Bryans is currently Chief Scientific Officer (Early Discovery) for Charles River Laboratories. He trained as a chemist at the universities of York and Oxford, the latter being as a post-doc under Professor Sir Jack Baldwin. Since then, he has gained over 30 years of experience in drug discovery at a number of biotechnology, pharma, and not-for-profit companies, including Parke-Davis, Pfizer, LifeArc, and now Charles River Laboratories. He has led integrated dug discovery teams developing new potential small molecule and antibody-based treatments for a wide range of conditions, resulting in the discovery of over 30 assets, and is cited as an inventor on over 50 patents. He holds an honorary professorship at Queen Mary University of London and teaches various aspects of drug discovery at QMUL, University College London, and the Wellcome Trust. He also sits on a range of advisory committees and panels and is a Fellow of the Royal Society of Chemistry.
.svg)
